Top 8 targeted protein degradation conferences of 2023 at a glance

Many methods used in fragment-based drug discovery pose real challenges — SPR often struggles to detect true hits due to fragments’ small mass, DSF can have high rates of false positives, and NMR equi

Transcription factors have traditionally been considered challenging therapeutic targets. Their intrinsic disorder and lack of small molecule binding pockets make them intractable to small molecule ap

Dianthus is a biophysical screening instrument that uses Spectral Shift technology to measure molecular interactions for hit ID, hit-to-lead, and lead optimization. It offers a 384-well plate format a

MYC is an important therapeutic target that associates with MAX to regulate gene transcription. Its lack of binding pockets and the presence of disordered regions make it a difficult protein to study

The development of your protein degrader is a multi-step and complex process usually packed with challenges that if left unsolved will delay the progress of your project. What if you could overcome co

Chances are your company’s research and development pipeline includes several PROTAC candidates — placing you with many others in the race to bring successful and efficient protein degraders to the cl

When you’re entrusted with developing therapeutics for challenging or undruggable targets, it’s a struggle to characterize molecular interactions. And it’s not for lack of effort or expertise — SPR an